Skip to main content
Text us Contact us
The pharmacology and neurobiology of psilocybin, explained

How Psilocybin Works

From the molecule to the mind — what is actually known about psilocybin in the body and the brain, level by level, and where the science runs out.

Six questions, not one

People who ask how psilocybin works are usually asking one of six different questions, and the answers are in very different states of repair. What the molecule is and what the body does with it is settled chemistry. Which receptor produces the experience is well established in people. How neurons change shape afterward rests mostly on cells and animals. What happens to whole brain networks is among the most cited work in the field and still needs replication. Why a person might hold a lifelong belief more loosely is a set of frameworks rather than findings.

This page takes them in order, smallest to largest, and says plainly how strong each layer is. Every claim links to its source. One thing is worth saying at the start: none of these accounts describes something the medicine does on its own, and the openings they describe can close again without the work around them.

In short

What it is
Psilocybin is inactive until the body converts it to psilocin.
Where it acts
Mainly one serotonin receptor, 5-HT2A, concentrated in the thinking parts of the cortex.
How we know
Block that receptor and the experience largely does not happen.
What lasts
A window of easier rewiring, shown in cells and animals, still being measured in people.
The honest part
No single account explains it yet, and the medicine does nothing on its own.

The six levels at a glance

How well supported each layer of the explanation is, as of late 2026.

1

The molecule

What enters the body, and what the body does with it

Well established
2

The receptor

Which lock the key fits, and where those locks sit

Well established in people
3

The cell

How neurons change shape afterward

Strong in cells and animals
4

The circuit

Which filters loosen during the experience

Partial human support
5

The network

How whole brain systems stop keeping to themselves

Needs replication
6

The mind

Why beliefs and habits can be held more loosely

Frameworks, not findings

First: what the trials actually show

Before any mechanism, it helps to be clear about what is being explained. Most of the clinical evidence for psilocybin is in depression, and the trials are still small by the standards of psychiatric medicine.

  • In a small randomized trial of adults with major depression, two psilocybin sessions with psychological support produced large reductions in symptoms compared with a delayed-treatment group (Davis et al., 2021).
  • In the largest trial so far, adults with treatment-resistant depression received a single session at one of three dose levels. The highest-dose group improved more than the lowest at three weeks. Whether that difference lasted was less clear, and adverse events, including suicidal thoughts and behavior, occurred across all groups (Goodwin et al., 2022).
  • In a trial comparing psilocybin with the antidepressant escitalopram over six weeks, the two did not differ significantly on the main depression measure. Some secondary measures favored psilocybin, but those were not the trial's main test (Carhart-Harris et al., 2021).

Research in anxiety around serious illness, alcohol use and other conditions is earlier still. There is also a non-pharmacological explanation any honest account has to include: in most psilocybin trials participants can tell whether they received the drug, which makes true blinding nearly impossible, and people who enroll often expect to benefit. Researchers have argued that expectancy and unblinding may account for part of the effects seen in trials (Muthukumaraswamy et al., 2021). That does not mean the effects are not real. It means the size of the drug's own contribution is still an open question.

Level 1

The molecule: psilocybin is not the active drug

The best-settled part of the whole story, and the part almost nobody describes correctly.

Psilocybin itself does very little. It is a prodrug: the body strips a phosphate group from it, by way of the enzyme alkaline phosphatase, and the result is psilocin, which is the compound that acts on the brain (Dinis-Oliveira, 2017). The conversion is thorough. In a pharmacokinetic study of oral psilocybin, no psilocybin at all could be found in plasma or urine (Brown et al., 2017). By the time anything reaches the brain, the drug in the bloodstream is psilocin.

From psilocybin to psilocin and out again Psilocybin, which is inactive, is converted by alkaline phosphatase into psilocin, the active compound. Psilocin is cleared mainly by glucuronidation in the gut and liver, with monoamine oxidase A and two liver enzymes playing minor roles. Psilocybin inactive as taken alkaline phosphatase Psilocin the active compound acts at 5-HT2A Glucuronidation main route out, gut and liver MAO-A, CYP2D6, CYP3A4 minor routes Schematic. Sources: Dinis-Oliveira 2017, Brown 2017, Manevski 2010, Thomann 2024.
Psilocybin is a prodrug. What acts on the brain is psilocin, and what carries it out of the body is mostly a sugar molecule attached in the gut and liver.

How psilocin leaves matters more than it sounds, because it decides which medications can interfere. The main exit is glucuronidation — an enzyme attaches a sugar group, making the molecule easy to excrete. The enzymes involved are UGT1A10 in the small intestine and UGT1A9 in the liver (Manevski et al., 2010). Monoamine oxidase A plays a minor part, and two liver enzymes, CYP2D6 and CYP3A4, play a smaller one still. The practical finding is the useful one: a person's CYP2D6 genotype did not change psilocin levels in blood, which suggests the common medications that inhibit that enzyme are unlikely to matter much for drug levels (Thomann et al., 2024) — though no study has given someone such an inhibitor and measured what happened. Neither did two weeks of an SSRI (Becker et al., 2022).

That is why most real medication interactions with psilocybin are not about drug levels at all. They happen at the receptor, or in the body's stress response — blunting of the experience, additive effects on blood pressure, a lowered seizure threshold — rather than through one drug raising or lowering the amount of another. Our guide to who should not take psilocybin covers how that plays out in screening.

Why the day has the shape it does

Why the day has the shape it does

The timing of a session is not a scheduling convention; it follows the molecule. Psilocin appears in blood quickly, reaches its peak around two hours after an oral dose, and has a short elimination half-life — roughly three hours measured as total psilocin, and under two hours for the unbound fraction that is actually psychoactive (Brown et al., 2017; Becker et al., 2022). Subjective effects in healthy volunteers lasted between five and a half and six and a half hours on average, longer at higher doses (Holze et al., 2023). That is the five-to-six hours described on our page about what happens in a session, and the reason a session is a full day rather than an appointment.

One more finding is worth knowing because it contradicts an intuition. Body weight did not predict how quickly people cleared psilocin, in either study that looked (Brown et al., 2017; Holze et al., 2023). Individual variation in the time course is real and substantial, but it is not explained by size.

The shape of a session, hour by hour Psilocin in the blood rises quickly, peaks around two hours and falls steadily. Subjective intensity follows it closely, building over the first two hours, holding through the middle of the session and easing by around six hours. 0h 1h 2h 3h 4h 5h 6h 7h 8h Hours after the medicine is taken. Schematic, not to scale. Sources: Brown 2017, Holze 2023, Madsen 2019. Intensity What the person experiences Psilocin in the blood
The experience tracks the molecule closely. In a PET study, how intense people rated the experience moved with both receptor occupancy and the amount of psilocin in their blood (Madsen et al., 2019).
Level 2

The receptor: one lock, in a very particular place

The strongest human evidence in the whole field, and the cleanest experiment.

Psilocin acts on several serotonin receptors, but one of them produces the experience: 5-HT2A. The evidence for that is not a correlation, it is a blockade. When volunteers were given ketanserin, a drug that blocks 5-HT2A, before psilocybin, most of psilocybin's effects on perception and consciousness did not happen. The same study found that risperidone, which also blocks that receptor, blunted the experience, while haloperidol, which blocks dopamine receptors instead, increased them (Vollenweider et al., 1998). Remove the one receptor and the state largely disappears; remove dopamine signaling and it does not. That experiment is almost thirty years old and it is still the load-bearing finding.

It also has a practical consequence that surprises people: giving someone an antipsychotic to end a difficult experience is the wrong reflex with psilocybin, and haloperidol in particular is a poor choice. What a difficult passage calls for is a person, a quiet room and time — which is the whole design of a supported session.

The second human finding comes from brain imaging. Using PET scanning, researchers measured how much of the 5-HT2A receptor population psilocybin actually occupied, and found that occupancy rose with dose, that psilocin blood levels and occupancy fit a simple binding model, and that both tracked how intense people rated the experience (Madsen et al., 2019). Higher occupancy, stronger experience. It is rare in psychiatry to have a chain that tight: a dose, a measurable fraction of receptors engaged, and a subjective state that moves with it.

Where the receptors sit in the cortex A cross-section of cerebral cortex showing six layers. A large output neuron sits in layer five, with a long branching dendrite reaching up toward the surface. The 5-HT2A receptors are concentrated along that upper dendrite rather than spread evenly through the tissue. I II III IV V VI Cortical layers, surface at top output neuron, layer V 5-HT2A receptor Densest where thinking is most layered Association cortex — the regions that handle complex thought and self-reflection — carries the highest density, with the receptor concentrated on the long upper dendrites of layer V output neurons. Also present in visual cortex, thalamus, amygdala and claustrum. Sources: Nichols 2016, Beliveau 2017.
The receptor is not spread evenly. It is concentrated on the apical dendrites of large output neurons in layer V of the cortex, and densest overall in the association cortex (Nichols, 2016). A high-resolution human atlas maps the whole serotonin system in the same way (Beliveau et al., 2017).

Geography is most of the explanation here. A drug that engaged serotonin receptors evenly across the brain would be a different drug. Psilocin's targets sit most densely in the parts of the cortex that handle layered, self-referential thought, and on the specific branches of neurons that gather incoming signals from far away. That is a reasonable place for a molecule to act if the result is going to be a change in how a person experiences their own mind rather than, say, a change in muscle tone.

Two further findings fill in the receptor picture. Structural biologists have now imaged the receptor in its activated state with a psychedelic bound to it, which is how drug designers reason about what makes one molecule psychedelic and another not (Kim et al., 2020). And a 2023 study built a series of molecules that engage the receptor's two internal signaling pathways to different degrees, then tested which pathway predicted psychedelic-like effects. One of them, the Gq pathway, predicted it; the other did not, and a threshold amount of Gq activation appeared to be required (Wallach et al., 2023). That is why some drugs bind the same receptor without being psychedelic at all — binding is not the same as switching it on in the particular way that matters.

Other receptors, and why tolerance builds so fast

Other receptors, and why tolerance builds so fast

5-HT2A is the headline but not the whole profile. Psilocin binds several serotonin receptor subtypes and interacts with the serotonin transporter and partly the norepinephrine transporter, which classic psychedelics such as LSD and mescaline do not; it does not meaningfully engage adrenergic or dopaminergic receptors the way LSD does (Rickli et al., 2016). Some of that secondary activity shows up in practice. A 5-HT1A drug given beforehand reduced the visual component of a psilocybin experience without flattening the experience as a whole (Pokorny et al., 2016).

The receptor system also adapts, and quickly. Daily dosing with indole psychedelics in rats reduced cortical 5-HT2 binding within a few days, and the reduction appeared and faded on roughly the same schedule as behavioral tolerance (Buckholtz et al., 1990). In ten healthy volunteers, a single dose did not change average receptor binding measured a week later; individual changes varied, and in a post hoc analysis a larger drop in binding went with a larger rise in self-reported mindfulness three months later (Madsen et al., 2020). Two things follow. A second experience a day or two after the first tends to be much weaker, which is one reason the sessions in a journey series are weeks apart. And nothing in this literature describes receptor damage; it describes a system that adjusts and returns.

Level 3

The cell: a window in which rewiring is easier

Strong evidence in cells and animals. The human version is still being measured.

The receptor story explains the experience. It does not explain why anything would be different a month later. The leading biological answer to that is neuroplasticity — the brain's ability to grow and reshape the connections between neurons.

In cultured neurons and in rodents, psychedelics promoted the growth of dendrites, of dendritic spines (the small protrusions where synapses form) and of new synapses, through signaling pathways long associated with plasticity (Ly et al., 2018). In mice, a single dose of psilocybin increased the number and size of dendritic spines in the frontal cortex within a day, and some of those new spines were still there more than a month later (Shao et al., 2021).

A 2023 result sharpened the picture considerably. The plasticity effect in cortical neurons appeared to depend on 5-HT2A receptors located inside the cell rather than only on its surface. Psychedelics cross cell membranes easily; serotonin does not. When researchers got serotonin inside the cell artificially, it produced plasticity too (Vargas et al., 2023). If that holds, the difference between a psychedelic and the brain's own serotonin is partly a question of access — which would explain why the brain is not constantly remodeling itself on its own supply.

Then there is a genuinely unresolved dispute. One group reported that LSD and psilocin bind directly to TrkB, the receptor for the growth factor BDNF, and that in mice the plasticity effects survived even when 5-HT2A signaling was blocked, while the hallucination-like behavior did not (Moliner et al., 2023). If that is right, the rewiring and the experience could run through different receptors entirely. The finding is contested, awaits independent replication, and sits awkwardly beside the intracellular account above. Both come from animal work.

Can you get the rewiring without the experience?

Can you get the rewiring without the experience?

Researchers have made compounds that promote plasticity in the laboratory without producing the behavioral signs of a psychedelic experience. One, a modified relative of ibogaine, showed plasticity and antidepressant-like effects in rodents (Cameron et al., 2021). Whether that carries over to people is unknown. The field is openly divided on whether the subjective experience is necessary for lasting benefit: some argue it is (Yaden and Griffiths, 2021), others that it may not be (Olson, 2021). This is a live debate, not a finding, and it matters commercially as well as scientifically — a plasticity drug without the experience would not need a seven-hour session or a licensed facilitator.

A related animal result is why clinicians care so much about the weeks after a session. Early in development the brain passes through critical periods, stretches of time when certain kinds of learning happen unusually easily. In mice, psilocybin, LSD, ketamine, MDMA and ibogaine all reopened a critical period for social reward learning — and how long it stayed open tracked how long each drug's acute effects last in people (Nardou et al., 2023). It is a striking result and it is a mouse result.

Bottom line: plasticity is currently the strongest biological explanation for why effects might outlast the session. In people, 5-HT2A's role in the acute experience is well established; the evidence for rewiring comes mostly from cells and animals, and the exact pathways are still debated.

Level 4

The circuit: which filters loosen

Good at explaining the experience. Quieter on why change would last.

A third set of accounts looks at specific circuits, mostly to explain what happens during a session.

The thalamic filter. The thalamus relays and gates information, regulating how much sensory and internal signal reaches the cortex. One long-standing model proposes that psychedelics loosen this gating, so more information arrives with less top-down filtering — which would help explain intensified perception and unusual associations (Vollenweider and Preller, 2020). In human imaging, LSD changed the thalamus's connections with the cortex, and a 5-HT2A blocker prevented those changes, which is partial support (Preller et al., 2018).

The claustrum. This is a thin sheet of neurons beneath the cortex, dense in 5-HT2A receptors and connected to nearly every cortical region, which appears to help coordinate cortical networks when a task requires focus. The proposal is that psychedelics disrupt that coordinating role (Doss et al., 2022). In people, psilocybin reduced claustrum activity and altered its connections with major brain networks (Barrett et al., 2020).

The amygdala. In healthy volunteers, psilocybin reduced amygdala reactivity to negative images, and the size of that reduction tracked the improvement in mood people reported (Kraehenmann et al., 2015). Depression is associated with an over-reactive amygdala, so this is one of the more direct bridges between the acute pharmacology and the clinical target.

Glutamate, region by region. Serotonin is where psilocin starts, but much of what follows is carried by glutamate, the brain's main excitatory messenger. Using high-field imaging, researchers found that psilocybin changed glutamate levels differently in different regions, and that those changes predicted the character of the experience: higher glutamate in the medial prefrontal cortex went with a negatively experienced dissolution of the sense of self, while lower glutamate in the hippocampus went with a positively experienced one (Mason et al., 2020). That is one of the few findings that speaks to why the same medicine produces a frightening passage for one person and a liberating one for another, and it is a single study.

Level 5

The network: systems stop keeping to themselves

Among the most cited work in the field, and the most in need of replication.

Brain imaging lets researchers watch how whole systems behave rather than single regions. Three observations recur.

Activity becomes more varied. The entropic brain hypothesis proposed that psychedelics increase the entropy of brain signals (Carhart-Harris et al., 2014). Entropy here is a statistical measure of variety, not disorder: activity becomes less predictable and covers a wider range of patterns than in ordinary waking consciousness.

Networks become less separate. Normally the brain's large networks are fairly distinct from one another. Under psychedelics they become less segregated and more cross-connected.

The default mode network changes most. The default mode network is active during self-referential thinking — rumination, mind-wandering, the running narrative about who we are. In an unusually intensive study, healthy adults were scanned roughly eighteen times each before, during and for weeks after a session. Psilocybin disrupted functional connectivity across the cortex far more than a stimulant comparison drug did, driven by desynchronization that dissolved the usual distinctions between networks. The effect was strongest in the default mode network, individual differences in it tracked the subjective experience closely, and one change — reduced connectivity between the anterior hippocampus and the default mode network — was still measurable weeks later (Siegel et al., 2024).

The finding tied most directly to clinical outcome comes from two depression studies: after psilocybin, brain networks became less modular and more globally integrated, and greater integration was associated with greater improvement. Escitalopram did not produce the same change (Daws et al., 2022).

Networks before and during the experience On the left, three groups of nodes are densely connected within themselves and barely connected to each other. On the right, the same nodes have fewer connections inside each group and many more between groups. Ordinary waking state During the experience Schematic illustration of a reported pattern, not imaging data. Sources: Carhart-Harris 2014, Siegel 2024, Daws 2022.
Less separation between networks, more traffic across them. This is the most widely cited description of the psychedelic brain state and also the one researchers most often caution about.

Bottom line: a review of psychedelic brain-imaging studies found that results have been inconsistent across studies, samples are often small, and analysis methods vary widely (McCulloch et al., 2022). These findings describe conditions that may make reorganization possible. They do not prove that it happened.

Level 6

The mind: beliefs held more loosely

The most clinically useful accounts, and the most speculative. These are frameworks, not established mechanisms.

Relaxed beliefs. The REBUS model starts from the idea that the brain constantly predicts its own experience using deeply held assumptions. Some of those are about the physical world; others are beliefs like "I am a burden" or "people leave." The proposal is that psychedelics temporarily reduce the confidence the brain places in its highest-level beliefs, so that incoming information from emotion, memory and the senses carries more weight than usual (Carhart-Harris and Friston, 2019). That creates an opening to revise beliefs that ordinarily feel like plain facts. Loosening cuts both ways: a belief held loosely can be revised in a healthier direction, or replaced by one just as rigid.

Canalization. A related idea borrows an image from developmental biology — a ball rolling down a landscape of valleys. Over time, and often in response to adversity, patterns of thought and behavior carve deeper valleys that become harder to leave. This account proposes that much psychopathology involves patterns that were once protective and have become rigid, and that psychedelics temporarily flatten the landscape so other paths become reachable (Carhart-Harris et al., 2023). Whether a new path is taken, and kept, depends on what happens afterward.

Pivotal mental states. These are brief, highly plastic states that can occur under extreme stress or in moments of insight, in which rapid psychological change becomes possible. The proposal is that psychedelics engage the same systems that evolved for them (Brouwer and Carhart-Harris, 2021). It also explains why the state that can open something valuable can destabilize a person without the right support.

What the experience itself predicts. Some features of the acute experience track outcomes. The best studied is mystical-type experience — a sense of unity, transcendence of time and space, and deep meaning. In treatment-resistant depression, people who reported stronger mystical-type experiences tended to improve more (Roseman et al., 2018). Emotional breakthrough and a sense of psychological insight have tracked outcomes too. These are associations, not proof of cause — each could reflect something else, such as how ready a person was for change.

The part the medicine cannot do alone

Every level above describes a temporary opening: a receptor system engaged, neurons more able to rewire, filters loosened, networks less rigid, beliefs held less tightly. None of them says what fills that opening. That depends on everything around the medicine.

Screening comes first. The same openness that makes change possible is why some people should not take psilocybin, and why a person's circumstances on the day matter. Our page on safety and screening explains the process, and our guide to who should not take psilocybin lays out the common rule-outs.

Preparation shapes what someone brings into a session — their intentions, their understanding of what may happen, their trust in the people supporting them. See how to prepare for a journey.

The setting and the relationship shape the session itself. Context is arguably not an add-on to psychedelic effects but part of the mechanism, and the more open the brain becomes, the more context matters (Carhart-Harris et al., 2018). Psychedelics also increase suggestibility: in one study, LSD made healthy volunteers more responsive to suggestion (Carhart-Harris et al., 2015). The words, expectations and presence of the people in the room carry more weight than usual, which is a responsibility before it is a tool. In one psilocybin trial for depression, a stronger therapeutic relationship was associated with more emotional breakthrough during the session and better outcomes afterward (Murphy et al., 2022). See what happens during a session and the role of music.

Integration is where insights become change. If the plasticity and canalization accounts are right, the days and weeks after a session are when new patterns take hold or the old ones reassert themselves. Integration also does a quieter job: sorting which realizations hold up. Insights under psychedelics can feel certain without being accurate, and researchers have argued that psychedelics can produce compelling false insights alongside true ones (McGovern et al., 2024). Talking an insight through, testing it against an ordinary week, and acting on the ones that survive is part of how change becomes durable. Our psychedelic integration page describes how that work is structured here.

Putting it together

No single model explains how psilocybin supports change. A fair summary of the evidence as of late 2026:

  • Settled: psilocybin is a prodrug converted to psilocin, which is cleared mainly by glucuronidation. The time course is short and the experience tracks it closely.
  • Well established in people: 5-HT2A activation drives the acute experience. Block the receptor and the state largely does not occur, and receptor occupancy tracks how intense the experience feels.
  • Strong in cells and animals: psychedelics promote structural plasticity, with the exact pathways still debated and the human evidence thinner.
  • Promising but needing replication: less segregated, more flexible network activity, including one clinical link between network integration and improvement in depression.
  • Frameworks with preliminary evidence: REBUS, canalization and pivotal mental states, plus experience-level predictors such as mystical-type experience.
  • Unresolved: how much of the benefit in trials comes from the drug itself rather than expectancy, how long benefits last, and whether the subjective experience is necessary at all.

What these accounts share is the idea that the medicine makes change more possible, not inevitable. Individual responses vary widely, the research is moving quickly, and nothing here is medical advice or a promise of outcome. The responsible path is legal, supervised use with careful screening, skilled support and real integration.

Full source list

Sources

Grouped by level. Where a paper is open access the link goes to the publisher; otherwise to PubMed.

The molecule

  • Brown RT, et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017. doi:10.1007/s40262-017-0540-6
  • Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017. doi:10.1080/03602532.2016.1278228
  • Holze F, et al. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin Pharmacol Ther. 2023. doi:10.1002/cpt.2821
  • Manevski N, et al. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos. 2010. PMC2835393
  • Thomann J, et al. In vitro and in vivo metabolism of psilocybin's active metabolite psilocin. Front Pharmacol. 2024. doi:10.3389/fphar.2024.1391689

The receptor

  • Becker AM, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther. 2022. doi:10.1002/cpt.2487
  • Beliveau V, et al. A high-resolution in vivo atlas of the human brain's serotonin system. J Neurosci. 2017. doi:10.1523/JNEUROSCI.2830-16.2016
  • Buckholtz NS, et al. Lysergic acid diethylamide administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology. 1990. PMID 1969270
  • Kim K, et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell. 2020. doi:10.1016/j.cell.2020.08.024
  • Madsen MK, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019. doi:10.1038/s41386-019-0324-9
  • Madsen MK, et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol. 2020. doi:10.1016/j.euroneuro.2020.02.001
  • Nichols DE. Psychedelics. Pharmacol Rev. 2016. doi:10.1124/pr.115.011478
  • Pokorny T, et al. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016. doi:10.1016/j.euroneuro.2016.01.005
  • Rickli A, et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016. doi:10.1016/j.euroneuro.2016.05.001
  • Vollenweider FX, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998. PMID 9875725
  • Wallach J, et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023. doi:10.1038/s41467-023-44016-1

The cell

  • Cameron LP, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021. PMID 33299186
  • Ly C, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018. PMID 29898390
  • Moliner R, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023. PMID 37280397
  • Nardou R, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023. PMID 37316665
  • Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021. PMID 33861218
  • Shao LX, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021. PMID 34228959
  • Vargas MV, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023. doi:10.1126/science.adf0435
  • Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021. PMID 33861219

Circuits and networks

  • Barrett FS, et al. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage. 2020. PMID 32454209
  • Carhart-Harris RL, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014. PMID 24550805
  • Daws RE, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022. PMID 35411074
  • Doss MK, et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2022. PMID 34897383
  • Kraehenmann R, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015. doi:10.1016/j.biopsych.2014.04.010
  • Mason NL, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020. doi:10.1038/s41386-020-0718-8
  • McCulloch DE, et al. Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses. Neurosci Biobehav Rev. 2022. PMID 35588933
  • Preller KH, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife. 2018. PMID 30355445
  • Siegel JS, et al. Psilocybin desynchronizes the human brain. Nature. 2024. doi:10.1038/s41586-024-07624-5
  • Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020. PMID 32929261

The mind, and the work around the medicine

  • Brouwer A, Carhart-Harris RL. Pivotal mental states. J Psychopharmacol. 2021. PMID 33174492
  • Carhart-Harris RL, et al. LSD enhances suggestibility in healthy volunteers. Psychopharmacology. 2015. PMID 25242255
  • Carhart-Harris RL, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018. PMID 29446697
  • Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019. PMID 31221820
  • Carhart-Harris R, et al. Canalization and plasticity in psychopathology. Neuropharmacology. 2023. PMID 36584883
  • McGovern HT, et al. An integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024. PMID 39242747
  • Murphy R, et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol. 2022. PMID 35431912
  • Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018. PMID 29387009

Clinical trials referenced

  • Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021. PMID 33852780
  • Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021. PMID 33146667
  • Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022. PMID 36322843
  • Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021. PMID 34038314

Common questions

Is psilocybin addictive?
Classic psychedelics are not considered reinforcing and do not produce dependence. The pharmacological reason given is that they lack the direct dopaminergic action that nearly every drug with dependence liability shares, and animal self-administration studies have been unsuccessful (Nichols, 2016). That is a statement about dependence, not about safety in general — the screening still matters.
Does psilocybin damage serotonin receptors?
Repeated daily dosing in rats reduced cortical 5-HT2 binding, which parallels how quickly tolerance builds and how quickly it fades (Buckholtz et al., 1990). In ten healthy volunteers, one dose did not change average receptor binding measured a week later (Madsen et al., 2020). Nothing in the research describes damage; it describes a receptor system that adjusts and then returns.
Why does tolerance build so fast?
Repeated exposure over consecutive days reduces the receptor response, so a second experience close behind the first tends to be markedly weaker (Buckholtz et al., 1990). This is one of several reasons sessions in a journey series are spaced weeks apart rather than days.
If my antidepressant acts on serotonin too, is that dangerous?
In a controlled study, two weeks of an SSRI did not change psilocin pharmacokinetics and did not add serotonergic risk; it reduced anxiety and cardiovascular effects while leaving the positive effects intact (Becker et al., 2022). Whether years of an antidepressant behave like two weeks is a separate and unsettled question, covered in our post on psilocybin and SSRIs. Any medication decision belongs to your prescriber.
Does the experience itself matter, or just the chemistry?
This is an open debate in the field. Some researchers argue the subjective experience is necessary for lasting benefit (Yaden and Griffiths, 2021); others argue it may not be (Olson, 2021). Compounds that promote plasticity without producing a psychedelic experience exist in the laboratory, but whether they help people is unknown.
Is this how the medicine is described at FRTC?
This page is background on the science. What we actually do is preparation, a supported session and integration under Colorado's Natural Medicine Health Act, after a screening. The mechanisms here describe an opening; the therapy is what fills it.

Important: this page describes research, not a treatment plan. Natural medicine services are not appropriate for everyone, and a thorough screening precedes any session. No outcome can be guaranteed, and nothing here is medical advice or a reason to start or stop any medication — those decisions belong to you and your prescriber.

Questions about any of this?

Tell us how to reach you and we'll get back to you — usually within one business day. Or book a free 15-minute call.

You’re asking about

Natural Medicine

We usually reply within one business day. What you write here is confidential — but please don’t include clinical details you wouldn’t want in an email, and if you’re in crisis, call or text 988.

Interested in a different program? Use our full contact form →